

| 2020 EFPIA DISCLOSURE (inc. Vaccines Europe) | | | | | | | | | | | | |
|--|--|---|-------------------------------|----------------------------------|--|--------------------------------------|---|-------------------|------------------------|---------------------------------|--|--|
| Date of publication: 14th of April 2021 | | | | | | | | | | | | |
| | Full Name | HCPs: City of Principal Practice HCOs: city where registered | Country of Principal Practice | Principal Practice Address | Unique country identifier <i>OPTIONAL</i> | Donations and Grants to HCOs and POs | Contribution to costs of Events | | | Fee for service and consultancy | | |
| | | | | | | | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees excl. VAT | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation | |
| HCPs | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as</i> | | | | | | | | | | | |
| | Eva Hofslil | Trondheim | Norway | St. Olavs hospital HF, Trondheim | | N/A | N/A | | | | 56.000 NOK | |
| | Ame Wibe | Trondheim | Norway | St. Olavs hospital HF, Trondheim | | N/A | N/A | | | | 10.000 NOK | |
| | | | | | | N/A | N/A | | | | | |
| | | | | | | N/A | N/A | | | | | |
| | | | | | | N/A | N/A | | | | | |
| | | | | | | N/A | N/A | | | | | |
| <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | | |
| Aggregate amount attributable to transfers of value to such Recipients | | | | | | N/A | N/A | | | | | |
| Number of Recipients in aggregate disclosure | | | | | | N/A | N/A | | | | | |
| % of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A | N/A | | | | | |
| HCOs | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as</i> | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | | |
| Aggregate amount attributable to transfers of value to such Recipients | | | | | | N/A | N/A | | | | | |
| Number of Recipients in aggregate disclosure | | | | | | N/A | N/A | | | | | |
| % of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A | N/A | | | | | |
| POs | <i>INDIVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | | |
| | Pancreas Nettverk Norge | Grant to support the pancreas day the 19th of November 2020 | | | | | 15.000 NOK | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | | |
| Aggregate amount attributable to transfers of value to such Recipients | | | | | | N/A | N/A | | | | | |
| Number of Recipients in aggregate disclosure | | | | | | N/A | N/A | | | | | |
| % of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A | N/A | | | | | |
| AGGREGATE DISCLOSURE | | | | | | | | | | | | |
| Transfers of Value re Research & Development as defined | | | | | | | | | | | | |
| N/A | | | | | | | | | | | | |

The amounts are without VAT